Skip to main content

Highlights

  1. 1
    Science (New York, N.Y.) · 2025
    PMID: 40080571DOISenior author38 citations
  2. 2
    Nature · 2020
    PMID: 32814897PMCID: PMC7785256DOISenior author220 citations
  3. 3
    Nature metabolism · 2022
    PMID: 35361954PMCID: PMC9050834DOISenior author91 citations

Publications

255 publications

Active

11 grants
  • PI
    Targeting Stress Hormone Receptor Signaling: Defining GR--MR Crosstalk in Triple-Negative Breast Cancer
    NCI · 2026–2031 · via NIH RePORTER
    R01CA316133-01
  • PI
    Signal Transduction to P70 S6 Kinase 1
    National Cancer Institute · 2025–2030
    R01CA301410-30A1
  • KP
    A systems-level approach to therapeutically target STING in cancer
    National Cancer Institute · 2025–2030
    R01CA282762-02
  • PI
    Mitogenic and Oncogenic Regulation of ERK/RSK Signaling
    National Cancer Institute · 2014–2029· 4 renewals
    R01CA046595-39
  • KP
    Dissecting the impact of tumor-intrinsic chromosomal instability on the cancer ecosystem
    National Cancer Institute · 2023–2028
    R01CA280572-04
  • PI
    Propionate metabolism and cancer
    National Cancer Institute · 2023–2028
    R01CA273357-04
  • KP
    Investigating the link between propionate metabolism and aging
    National Institute on Aging · 2024–2027
    K99AG084860-01A1
  • PI
    Dissecting the role of folate deficiency in lung cancer development and genomic instability
    U.S. Department of Defense · 2024–2027
    HT9425-24-1-0299
  • Sub-PI
    Targeting BRCA1-mutant breast cancer cells with folate and vitamin C
    Breast Cancer Research Foundation · 2024–2026 · via Dana-Farber Cancer Institute
    BCRF-24-022
  • MPI
    MSK SPORE in Genomic Instability in Breast Cancer (DRP PP4: Non-Coding Mutations in Triple-Negative Breast Cancers)
    National Cancer Institute · 2024–2026 · via Memorial Sloan Kettering Cancer Center· 2 renewals
    P50CA247749-05
  • MPI
    Targeting BRCA1/2-deficient cancers with folate and vitamin C
    National Cancer Institute · 2024–2026
    R03CA289863-02
Completed grants (22)
  • PI
    The role of NAGK cysteine deprotonation in nutrient stress and cancer progression
    National Cancer Institute · 2023–2025
    R03CA280299-02
  • PI
    Folate deficiency as a source of genotoxic formaldehyde in cancer
    Cornell University - Ithaca · 2024–2024
    CU 235791-01
  • Sub-PI
    Targeting BRCA1-mutant breast cancer cells with folate and vitamin C
    Breast Cancer Research Foundation · 2022–2024 · via Dana-Farber Cancer Institute
    DFCI 224656-02
  • PI
    Signal Transduction to P70 S6 Kinase 1
    National Institute of General Medical Sciences · 2014–2024· 3 renewals
    R01GM051405-29
  • KP
    Targeting cysteine susceptibility in glioblastoma
    National Institute of Neurological Disorders and Stroke · 2022–2024
    K08NS128263-01
  • PI
    Establishing the role of Methylmalonic Acid in KRAS-mutated Lung Adenocarcinoma
    Conquer Cancer Foundation of the American Society of Clinical Oncology · 2022–2023
    ASCO 221296-01
  • MPI
    Molecular and Translational Oncology Research
    National Cancer Institute · 2017–2023Training
    T32CA203702-01A1
  • PI
    Addgene 706196
    Addgene, Inc. · 2022–2023
    Addgene 706196
  • PI
    Addgene 705684
    Addgene, Inc. · 2022–2023
    Addgene 705684
  • PI
    Targeting Cellular Protein Kinases As Treatment For COVID-19
    Pershing Square Foundation · 2020–2021
    PSF 210730-01
  • PI
    Biochemical and genetic investigation of oncogenic TOR-dependent regulation of RNA metabolism and tumorigenesis using cross-species approaches
    Starr Cancer Consortium · 2018–2020
    I11-0015
  • KP
    The Role of Histone H3 Variants in Breast Cancer Metastasis
    Susan G. Komen Breast Cancer Foundation, Inc. · 2017–2020Fellowship
    PDF17481555
  • KP
    Propionate Metabolism as an Essential Metabolic Adaptation for Tumor Progression
    National Cancer Institute · 2017–2020Career
    K99CA218686-02
  • PI
    Nuclear MAPK Translocation as a Therapeutic Target
    United States Israel Binational Science Foundation · 2016–2020
    2015082
  • PI
    Metabolic Regulation of mTORC1 Catalytic Activity
    U.S. Department of Defense · 2017–2020
    W81XWH-17-1-0118
  • PI
    Sanofi Innovation Award (iAward)
    Sanofi S.A. · 2018–2019Contract
    SUS 192927-01
  • KP
    Exploring the Regulation and Function of Gap Junction-Mediated Signaling in Glioblastoma Multiforme
    National Cancer Institute · 2017–2019Fellowship
    F32CA217048-02
  • PI
    Molecular and Biochemical Basis of Lymphangioleiomyomatosis
    National Heart, Lung, and Blood Institute · 2015–2018
    R01HL121266-02
  • PI
    The Role of CAF-1 Complex in Tumor Progression
    National Cancer Institute · 2016–2018
    R03CA212562-02
  • PI
    Mitogenic and Oncogenic Regulation of ERK/RSK Signaling
    NCI · 1988–2013 · via NIH RePORTER
    R37CA046595-26
  • PI
    FASEB Conference on Protein Kinases
    NCI · 2007–2012 · via NIH RePORTER
    R13CA130582-02
  • PI
    Development of a high content cell based screen for inhibitors of the mTOR signal
    NINDS · 2007–2009 · via NIH RePORTER
    R21NS059428-01S1

Honors & distinctions

1 honor
  • Damon Runyon Fellowship / Grant · Damon Runyon Cancer Research Foundation · 1983

Clinical research

1 study

Active

1 study
  • PI
    Folate and DNA Damage in Patients with Lung Cancer
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)

Available technologies

News mentions

Show 4 more mentions

Media highlights

1 clip
6 PhD students · 11 Postdocs

External relationships

Leadership Roles

Elikia INC

Ownership

Elikia INC